Corton Capital Inc. Ionis Pharmaceuticals Inc Transaction History

Corton Capital Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$42.03 - $53.55 $35,515 - $45,249	-845 Reduced 7.36%	10,631 $460,000
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $111,989 - $133,257	2,581 Added 29.02%	11,476 $580,000
Q3 2023 Nov 14, 2023	BUY	$38.5 - $47.13 $75,691 - $92,657	1,966 Added 28.37%	8,895 $403,000
Q2 2023 Aug 14, 2023	SELL	$34.73 - $43.33 $73,315 - $91,469	-2,111 Reduced 23.35%	6,929 $284,000
Q1 2023 May 15, 2023	SELL	$33.58 - $41.2 $120,820 - $148,237	-3,598 Reduced 28.47%	9,040 $323,000
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $119,340 - $149,561	3,215 Added 34.12%	12,638 $477,000
Q3 2022 Nov 14, 2022	BUY	$36.54 - $48.66 $37,453 - $49,876	1,025 Added 12.21%	9,423 $417,000
Q2 2022 Aug 15, 2022	SELL	$31.71 - $43.0 $13,032 - $17,673	-411 Reduced 4.67%	8,398 $311,000
Q1 2022 May 16, 2022	BUY	$29.88 - $37.04 $263,212 - $326,285	8,809 New	8,809 $326,000

389

125M

2.25M

510K

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.64B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

Get notified when there are updates to the investment portfolio of Corton Capital Inc., based on Form 13F filings with the SEC.

Stay updated on Corton Capital Inc. with notifications on news.